Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US09062X1037
Ticker BIIB
Company BIOGEN
Currency $
Price
Aware Investor Index (AII) 0.9009
Recommendation BUY
P/E 33.80
ROE 15.82 %
Capitalization 67,463,490,000 $
Dividend Yield 0.00 %
P/S 5.50
AII Position 259
P/E Position 494
ROE Position 206
Capitalization Position 118
Dividend Yield Position 596
Sales 12,273,900,000 $
10-Year Average Earnings 1,995,900,000 $
Shares Outstanding 213,000,000
Equity 12,612,800,000 $
Dividend per Share 0 $
Industry Biotechnology
Country United States
BIOGEN Investor Relations Web Site http://investors.biogen.com/investor-relations







Sales:

YEAR MONTH AMOUNT
2017 12 12,273,900,000.00 $
2016 12 11,448,800,000.00 $
2015 12 10,763,800,000.00 $
2014 12 9,703,300,000.00 $
2013 12 6,932,200,000.00 $
2011 12 5,516,500,000.00 $
2010 12 5,048,600,000.00 $
2009 12 4,716,400,000.00 $
2008 12 4,377,300,000.00 $
2007 12 4,097,500,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 2,539,100,000.00 $
2016 12 3,702,800,000.00 $
2015 12 3,547,000,000.00 $
2014 12 2,934,800,000.00 $
2013 12 1,862,300,000.00 $
2012 12 1,380,000,000.00 $
2011 12 1,234,400,000.00 $
2010 12 1,005,300,000.00 $
2009 12 970,100,000.00 $
2008 12 783,200,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 12,612,800,000.00 $
2016 12 12,140,000,000.00 $
2015 12 9,372,800,000.00 $
2014 12 10,809,000,000.00 $
2013 12 8,620,200,000.00 $
2012 12 6,961,500,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 213,000,000
2016 12 218,800,000
2015 12 231,200,000
2014 12 237,200,000
2013 12 238,300,000
2012 12 239,700,000

 












Bloomberg News for BIOGEN:



Google News for BIOGEN:

Nasdaq - 2 days ago
Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis
Biogen Inc. BIIB announced that it has obtained a worldwide license to develop and commercialize Ionis Pharmaceuticals' IONS pipeline ...
Seeking Alpha - 30 Nov 2018
Biogen Outlook For The 2020s
Today, I will focus on one biotech pharmaceutical company that is likely to richly reward investors between now and 2029: Biogen (BIIB).
EN Digest
Biogen (BIIB) Exercises Option with Ionis (IONS) to Develop ...
Biogen Inc (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Biogen exercised its option to obtain from ...
StreetInsider.com - 3 days ago
Biogen in-licenses ALS candidate from Ionis
Encouraged with positive early-stage data, Biogen (NASDAQ:BIIB) exercises its option to develop and commercialize Ionis Pharmaceuticals' ...
Seeking Alpha - 3 days ago
Investors Will Be Taking Another Look at Biogen Inc. (NASDAQ:BIIB ...
Biogen Inc. (NASDAQ:BIIB) has been in the news after the price of the stock hit $316.73 at the conclusion of the most recent close. The stock is ...
The Coin Guild - 14 hours ago
Traders Sell Biogen (BIIB) on Strength (BIIB)
Traders sold shares of Biogen Inc (NASDAQ:BIIB) on strength during trading hours on Thursday. $105.05 million flowed into the stock on the ...
The FinReviewer
Biogen's (BIIB) Management Presents at Evercore ISI, HealthconX ...
Biogen Inc. (NASDAQ:BIIB) Evercore ISI, HealthconX Call November 28, 2018 10:30 AM ET. Executives. Jeffrey Capello – Chief Financial ...
EN Digest
A Closer Look At Biogen Inc's (NASDAQ:BIIB) Impressive ROE
We'll use ROE to examine Biogen Inc (NASDAQ:BIIB), by way of a worked example. Over the last twelve months Biogen has recorded a ROE of ...
Thorold News
Exploring Analyst Views on Shares of Biogen Inc. (NASDAQ:BIIB)
Monitoring some price target data, we have noticed that shares of Biogen Inc. (NASDAQ:BIIB) currently have an average target of $386.16.
Fairfield Current - 2 days ago
Smith Asset Management Group LP Has Lowered Biogen (BIIB ...
Smith Asset Management Group LP Has Lowered Biogen (BIIB) Holding By $37.15 Million; Walleye Trading Decreased Its Netscout Sys (Put) ...


Back